FLUTICASONE
Leukemia, Lymphocytic, Chronic, B-Cell
Virginia Commonwealth UniversitySmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Leukemia, Lymphocytic, Chronic, B-Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pirtobrutinib Newave Pharmaceutical Inc | Phase 3 | BB |
Venetoclax Zulfa Omer | Phase 3 | BB |
Jcar017 (Lisocabtagene Maraleucel) Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 3 | B |
Sargramostim Virginia Commonwealth University | Phase 2 | B |
Plerixafor David Rizzieri, MD | Phase 2 | B |
View all 38 →
Same molecule, other indications
FLUTICASONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →